-- Merck KGaA Says REFLEX Study on Rebif Meets Primary Endpoint
-- B y   M i k e   G a v i n
-- 2010-10-25T09:08:28Z
-- http://www.bloomberg.com/news/2010-10-25/merck-kgaa-says-reflex-study-on-rebif-meets-primary-endpoint.html
Merck KGaA said the phase 3 REFLEX
study met its primary endpoint by demonstrating that Rebif
“significantly delayed conversion to multiple sclerosis”
diagnosed according to the McDonald criteria in patients with a
first clinical event suggesting the disease. The company
commented in an e-mailed statement today.  To contact the editor responsible for this story:
Mike Gavin at 
 mgavin2@bloomberg.net  